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The mouse hepatitis coronavirus (MHV) infects murine cells by binding of its spike (S) protein to murine
CEACAM1a. The N-terminal part of this cellular receptor (soR) is sufficient for S binding and for subsequent
induction of the conformational changes required for virus-cell membrane fusion. Here we analyzed whether
these characteristics can be used to redirect MHV to human cancer cells. To this end, the soR domain was
coupled to single-chain monoclonal antibody 425, which is directed against the human epidermal growth factor
receptor (EGFR), resulting in a bispecific adapter protein (soR-425). The soR and soR-425 proteins, both
produced with the vaccinia virus system, were able to neutralize MHV infection of murine LR7 cells. However,
only soR-425 was able to target MHV to human EGFR-expressing cancer cells. Interestingly, the targeted
infections induced syncytium formation. Furthermore, the soR-425-mediated infections were blocked by heptad
repeat-mimicking peptides, indicating that virus entry requires the regular S protein fusion process. We
conclude that the specific spike-binding property of the CEACAM1a N-terminal fragment can be exploited to
direct the virus to selected cells by linking it to a moiety able to bind a receptor on those cells. This approach
might be useful in the development of tumor-targeted coronaviruses.
The search for additional cancer therapies continues as
many different nonconventional approaches are being ex-
plored. The use of viruses in the fight against cancer started
already in the 1950s, and several oncolytic vectors are now
being evaluated in clinical trials (28, 30). The mouse hepatitis
coronavirus (MHV) possesses several attractive features that
suggest its possible use as an oncolytic virus. These include fast
replication, syncytium formation, and cell killing, as well as
species specificity. However, in order to exploit its oncolytic
potential, the ability to redirect the virus to human cancer cells
is a prerequisite. In order to achieve tumor-specific virus entry,
different targeting approaches have been explored for a variety
of viruses. These include pseudotyping, modification of viral
surface proteins, and the use of bispecific adapters (14, 28, 37).
MHV belongs to the family Coronaviridae, a family of large
(approximately 30-kb), positive-strand RNA viruses. MHV dis-
plays high species specificity, determined by the interaction
between the virus spike (S) protein and the virus receptor (3).
The S protein is a type I glycoprotein, synthesized as a 180-kDa
glycosylated precursor that is posttranslationally cleaved into
two 90-kDa subunits, S1 and S2 (13). The spike N-terminal S1
subunit is responsible for binding to the MHV receptor, which
results in a conformational change of the S2 subunit, mediating
the fusion of the virus envelope and the cell membrane. Key
events in this fusion process are the insertion of an as-yet-
unidentified fusion peptide present in the S protein into the
cell membrane and the coalescence of the heptad repeat re-
gions, HR1 and HR2, into a tightly associated six-helix bundle
(2, 31).
MHV infects murine cells via receptors belonging to the
carcinoembryonic antigen family of glycoproteins in the immu-
noglobulin (Ig) superfamily, called murine CEACAMs (1, 7, 8,
38). Results from infection studies with mice have shown that
mCEACAM1a is the major receptor for MHV strain A59 (18).
Through analysis of recombinant forms of CEACAM1a, it was
established that the N-terminal domain is responsible for virus
binding (9, 36). Crystallization studies revealed that this do-
main resembles an Ig-like fold and identified the amino acids
responsible for interaction with the S protein (33). Further-
more, it was reported that incubation of virions with anchorless
soluble receptor proteins caused a marked increase in the
hydrophobicity of the virions, which was associated with a
conformational change in S2 and neutralization of infection of
murine cells (24, 34, 40).
The aim of our studies is to investigate the possibilities of
using animal coronaviruses as oncolytic vectors for human use.
This requires specific targeting of the viruses to antigens (over)
expressed on tumor cells. Our approach is to engineer bifunc-
tional adapters of which, when functioning, the sequence will
be incorporated genomically into the virus to create a self-
targeted vector. In a previous study, we showed that the feline
infectious peritonitis coronavirus (FIPV) could be redirected
to human cancer cells expressing the epidermal growth factor
receptor (EGFR) via a bispecific single-chain antibody capable
of binding simultaneously to the FIPV spike protein and to the
human EGFR. The same adapter was also able to target
fMHV, an MHV derivative carrying the FIPV spike protein, to
the EGFR (39). Unfortunately, subsequent attempts to
genomically incorporate the adapter sequence failed; the virus
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appeared to be unstable and rapidly lost the inserted sequence
(unpublished observations). In the present study, we therefore
took a fundamentally different approach by designing an
adapter of a different nature. We hypothesized that the N-
terminal domain of CEACAM1a (soR), when fused to a can-
cer cell-binding ligand, could also be used as a bridging
adapter. To demonstrate this principle, the soR part was fused
to single-chain monoclonal antibody (MAb) 425 directed
against the EGFR and analyzed for its capacity to mediate
EGFR-specific entry of MHV into human cancer cells. The
results show that although the binding of the soR moiety to the
S protein presumably triggers in the viral spike the conforma-
tional changes that normally initiate the membrane fusion pro-
cess, these events do not inactivate the particles but allow the
fusion process to ensue as soon as the virus-adapter complex
has docked with the cell receptor.
MATERIALS AND METHODS
Viruses, cells, and antibodies. Stocks of MHV-EFLM (5) and fMHV (21)
were produced and titrated as before; MHV-EFLM is a derivative of MHV
strain A59 that contains a firefly luciferase gene between the E and M genes (5).
Recombinant vaccinia virus vTF7-3 containing the bacteriophage T7 RNA poly-
merase gene was used as a T7 RNA polymerase source for T7 promoter-driven
production of the soR adapter proteins in OST7-1 cells (10). OST7-1 (10)
(obtained from B. Moss), BHK-21 (American Type Culture Collection [ATCC]),
A431 (ATCC), and LR7 (21) cells were grown in Dulbecco’s modified Eagle’s
medium (Cambrex Bio Science, Verviers, Belgium) containing 10% fetal bovine
serum, 100 IU of penicillin/ml, and 100 g of streptomycin/ml (all from Life
Technologies, Ltd., Paisley, United Kingdom). Rabbit antiserum k134, raised
against purified MHV, was described previously (29). Polyclonal antibody anti-
N-CEACAM-Fc, directed against the mCEACAM1a N domain, was kindly pro-
vided by T. Gallagher (15). Anti-Myc antibody 9E10 (culture supernatant from
hybridoma cell line 9E10 [ATCC]) was used to detect Myc-tagged adapter
proteins.
Construction of soR adapters. To obtain the gene encoding the N-terminal
domain of the mCEACAM1a receptor (henceforth referred to as soR), a PCR
was performed on plasmid pCEP4:sMHVR-Ig (kindly provided by T. Gallagher
(15) with forward primer 2296 (5-CATGGGCCCAGCCGGCCGAGCTGGCC
TCAGCACAT-3) and reverse primer 2297 (5-CATGGCGGCCGCGGGGTG
TACATGAAATCG-3). In addition, PCRs were performed on the same plas-
mid with primers 2296 and 2298 (5-TGTCACAAGATTTGGGCTGGGGTGT
ACATGAAATCG-3), 2296 and 2299 (5-CGGTGGGCATGTGTGAGTTTT
GTCACAAGATTTG-3), and 2296 and 2300 (5-CATGGCGGCCGCTGGGC
ACGGTGGGCATGTGT-3) to generate a similar soR fragment with a 3
extension encoding a hinge linker region derived from human IgG1 (15). The
resulting DNA fragments, soR (429 nucleotides) and soR-h (472 nucleotides),
contained a 5 SfiI site and a 3 NotI site (underlined in the primers) and were
subsequently cloned with these restriction enzymes into the expression vector
pSecTag2 (Invitrogen, Breda, The Netherlands). The resulting expression vec-
tors, pSTsoR and pSTsoR-h, encode the N domain of mCEACAM1a in fusion
with an amino-terminal Ig signal sequence and a carboxy-terminal myc-His tag
under the control of a cytomegalovirus and a T7 promoter. The hinge region in
pSTsoR-h is located directly downstream of the N domain of mCEACAM1a.
Single-chain MAb 425, directed against EGFR, was isolated from pSTCFS11-
425 (17, 26) by NotI digestion and ligated in a VH-VL configuration into the NotI
site downstream of the soR and soR-h sequences in pSTsoR and pSTsoR-h,
creating a three-Ala linker between the soR and single-chain fragments, resulting
in expression vectors pSTsoR-425 and pSTsoR-h-425. The composition of the
adapter genes was confirmed by sequencing.
Production and analysis of soR constructs. For production of the soR adapter
proteins, subconfluent monolayers of OST7-1 cells were inoculated at a multi-
plicity of infection (MOI) of 5 with vTF7-3 (t  0 h) and transfected (t  1 h)
with pST-soR, pST-soR-h, pST-soR-425, or pST-soR-h-425 or mock transfected
by using Lipofectin (Life Technologies, Ltd., Paisley, United Kingdom). The
medium was refreshed at t  4.5 h, harvested at t  20 h, and centrifuged for 10
min at 3,000 rpm to clear it of cell debris. The supernatants containing the soR
proteins were loaded onto a 20% sucrose cushion and centrifuged for 30 min at
13,000 rpm to clear them of vTF7-3 virus prior to 20-fold concentration with
Vivaspin columns. The protein batches were aliquoted and stored at 20°C.
Western blot assay. The concentrated soR adapter protein preparations were
analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and sub-
sequent blotting on a polyvinylidene difluoride membrane (Bio-Rad Laborato-
ries, Hercules, CA). To block nonspecific antibody binding, the blot was incu-
bated in blocking buffer (phosphate-buffered saline [PBS] containing 5%
Protivar and 0.05% Tween 20) for 30 min at room temperature. Incubation was
continued with anti-N-CEACAM-Fc antibodies diluted 1:3,000 in blocking
buffer for 1 h at room temperature, followed by swine anti-rabbit peroxidase
(DAKO, Glostrup, Denmark) diluted 1:3,000 in blocking buffer for 1 h at room
temperature. Finally the blot was incubated with a 1:1 mixture of luminol and
enhancer (Amersham Pharmacia Biotech Europe GmbH, Freiburg, Germany)
and analyzed with Hyperfilms (Amersham Pharmacia Biotech Europe GmbH)
according to the manufacturer’s protocol.
Anti-N-CEACAM-Fc dot blot assay. The concentration of the soR proteins in
our concentrated preparations was determined by dot blot analysis. Serial dilu-
tions in a total volume of 50 l were blotted onto a nitrocellulose membrane with
a vacuum pump. A standard curve of purified N-CEACAM-Fc protein (100 nM)
was prepared in parallel to estimate the concentration of the soR adapter
proteins in our preparations. The immunoassay with antibodies directed against
N-CEACAM-Fc was performed as described above for the Western blot assay.
The density per square millimeter of each dot was measured with a densitometer
(Bio-Rad Laboratories) and plotted against the corresponding dilution factor,
after which the soR protein concentrations were calculated. The different prep-
arations were brought to the same concentration with culture medium before
use.
Determination of luciferase expression. At the indicated time points, the
culture media were removed and the cells were lysed with the appropriate buffer
provided with the firefly assay system (Promega). Intracellular luciferase expres-
sion was measured according to the manufacturer’s instructions, and the relative
light units were determined with a LUMAC biocounter M2500.
Anti-MHV immunostaining. Cells inoculated with MHV or fMHV in the
presence or absence of adapter protein were fixed with PBS containing 3.7%
paraformaldehyde, permeabilized with PBS containing 1% Triton X-100, and
subsequently incubated with k134 anti-MHV serum diluted 1:300, followed by
swine anti-rabbit peroxidase (DAKO, Glostrup, Denmark) diluted 1:300, both in
PBS containing 5% fetal bovine serum. The cells were stained with AEC (Brun-
schwig, Amsterdam, The Netherlands) according to the manufacturer’s protocol
and analyzed by light microscopy.
Antibody blocking experiments. To determine whether soR-425 and soR-h-
425 interact with the EGFR, 105 A431 cells per 0.32-cm2 well were incubated
with or without 100 l hybridoma supernatant containing MAb 425 for 30 min at
4°C. Next, the cells were inoculated with 104 tissue culture infective doses
(TCID50) of MHV-EFLM preincubated for 1 h at 4°C with 0.5 nM soR-425 or
soR-h-425 and were incubated for 1 h at 37°C. The cells were washed, and
incubation was continued for 20 h, after which they were lysed and luciferase
expression was measured.
Analysis of the effect of mHR2 on coronavirus infection. The effect of fusion-
inhibitory peptide mHR2 on the targeted infection process was analyzed by
preparing in parallel three sets of inoculation mixtures. MHV-EFLM at 104
TCID50 was preincubated in duplicate with 5 nM soR-425, soR-h-425, or mock
supernatant for 1 h at 4°C. To one of each set of mixtures, mHR2 peptide was
added to a concentration of 20 M. Cultures of 105 human A431 cells were
washed with PBS and inoculated with the infection mixtures for 1 h at 37°C. The
cells were then washed and incubation continued for 20 h. Finally, the cells were
lysed and luciferase activity was measured.
Monitoring of productive infection. A431 cells were seeded at 5  105/10-cm2
well and inoculated the next day with 2.5  106 TCID50 MHV-EFLM in the
presence or absence of adapter protein for 1 h. The cells were washed three times
with PBS and cultured for up to 48 h. At several time points after inoculation, a
small sample of the medium was harvested, centrifuged for 10 min at 3,000 rpm,
and stored at 80°C until analysis. The amount of virus produced at each time
point after inoculation was determined by endpoint dilution on murine LR7 cells.
Measurement of soR-425-mediated cell-cell fusion. A431 cells at 5  104/0.32-
cm2 well were inoculated for 2 h with 5  104 TCID50 MHV-EFLM preincu-
bated with 5 nM soR-425 for 1 h at 4°C. The cells were washed three times with
PBS and incubated further in the presence or absence of 5 nM soR-425, soR-
h-425, or mock control supernatant. Immunostaining was performed at 24 h after
inoculation, and the number of nuclei per syncytium was determined by counting
under a light microscope.
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RESULTS
Construction and analysis of soR adapter proteins. In order
to redirect MHV to receptors overexpressed on human cancer
cells, different adapter proteins were designed that were com-
posed of the N domain of CEACAM1a (soR) fused to anti-
EGFR single-chain MAb 425 (soR-425). In addition, adapter
proteins were constructed in which an IgG Fc hinge region—
responsible for disulfide linkage of IgG heavy chains—was
present between soR and single-chain MAb 425 (soR-h-425).
Similar constructs composed of the CEACAM1a N domain
only, named soR and soR-h, functioned as control proteins for
the soR-425 and soR-h-425 adapters (Fig. 1). The proteins
were expressed in OST7-1 cells by vTF7-3 infection and sub-
sequent transfection with the expression constructs. Their ex-
pression was confirmed by immunostaining of the cells with
anti-Myc and anti-N-CEACAM-Fc antibodies (data not
shown). Next, release of the soluble receptor proteins into the
culture medium was demonstrated by Western blotting (Fig.
2A, left side). The apparent molecular masses of soR, soR-h,
soR-425, and soR-h-425 were slightly higher than those calcu-
lated (18.9, 20.6, 46.0, and 47.6 kDa, respectively), because of
their glycosylation (data not shown). To determine whether the
presence of a hinge region resulted in protein dimerization, the
proteins were analyzed by sodium dodecyl sulfate-polyacrylam-
ide gel electrophoresis under nonreducing conditions, followed
by Western blotting with anti-N-CEACAM-Fc antibodies (Fig.
2A, right side). Dimerization was indeed observed for soR-h
and soR-h-425, but not for soR and soR-425, which lack the
FIG. 1. Schematic diagram of the soR constructs used in this study.
Native mCEACAM1a[1,4] is composed of two ectodomains (N and
A2) and contains a signal sequence (SS). The N and A2 domains are
linked to the transmembrane (TM) and cytoplasmic (Cy) domains. The
soluble receptor constructs are depicted below mCEACAM1a[1,4],
i.e., the CEACAM1a N domain (soR), the Ig hinge region (h), and
single-chain MAb 425 (425). The different soR proteins contain an Ig
leader sequence for secretion and a myc-His tag for detection.
FIG. 2. Immunoblot analysis of the soR adapter proteins. (A) Western blot analysis of the soR adapter proteins in the presence (left side) and
absence (right side) of -mercaptoethanol. kD, kilodaltons. (B) Anti-N-CEACAM-Fc dot blot analysis was used to equalize the soR protein
concentrations in the different batches. Twofold dilutions were made and analyzed for reactivity with anti-N-CEACAM-Fc antibody. In addition,
the adapter concentration in the soR preparation was determined by an anti-N-CEACAM-Fc dot blot assay in which a standard curve of purified
N-CEACAM-Fc protein (100 nM) was used to estimate the concentration of the soR adapter batches, as shown here for soR-425.
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hinge region. Dimerization was, however, not complete as also
monomers of the hinge-containing proteins were detected. The
different soR adapter batches were titrated with the anti-N-
CEACAM-Fc dot blot assay and diluted to the same concen-
tration of anti-N-CEACAM antibody-reacting protein (Fig.
2B, left side). The concentrations of the soR adapter batches
used were 25 to 50 nM, as determined by comparison to a
standard of N-CEACAM-Fc protein (Fig. 2B, right side).
Soluble receptor-mediated neutralization of MHV infection
on murine cells. Various forms of the CEACAM1a ectodo-
mains can neutralize MHV by binding to the MHV spike
protein (24, 34, 40). To evaluate the binding of the soR pro-
teins to the virus, neutralization experiments were carried out.
MHV-EFLM (5), a recombinant MHV-A59 strain containing
a firefly luciferase reporter gene, was preincubated with vari-
ous amounts of soR or its derivatives. After inoculation for 1 h,
the LR7 cells were washed and incubation continued for 7 h,
after which luciferase activity was measured (Fig. 3). All
adapter proteins appeared to have neutralized viral infectivity,
as opposed to infections carried out in the presence of mock
control supernatant. Strikingly, the presence of a hinge region
in the proteins resulted in increased neutralizing activity com-
pared to the proteins lacking this region. Moreover, fusion of
single-chain MAb 425 to the soR domain resulted in decreased
neutralization efficiency compared to soR alone. This effect,
however, was completely normalized to soR neutralization lev-
els by the presence of the hinge region in soR-h-425.
Soluble receptor-mediated MHV infection of cells express-
ing human EGFR. To determine whether MHV can be redi-
rected via the N domain of mCEACAM1a to cells lacking the
MHV receptor, MHV-EFLM was preincubated with 0.5 nM
soR-425 or with mock supernatant. The viruses were inocu-
lated for 1 h onto EGFR-overexpressing human A431 cancer
cells, after which the cells were washed and incubated further.
At several time points after inoculation, intracellular luciferase
expression was monitored to determine whether MHV infec-
tion was taking place. As shown in Fig. 4A, significant lucif-
erase expression became measurable at 9 h after inoculation
and reached a maximum at 20 h after inoculation, indicating
that MHV-EFLM had successfully entered the human cancer
cells in the presence of soR-425. That this infection was de-
pendent on the activity of the adapter protein was evident from
the lack of luciferase expression in its absence.
Next, the efficiencies of the targeted infections established
by soR-425 and soR-h-425 were compared. To this end, MHV-
EFLM was inoculated for 1 h on human A431 cells in the
presence of different amounts of the soR adapter proteins. The
cells were washed, and incubation was continued in normal
culture medium. After 20 h, the cells were lysed and luciferase
expression was measured. Figure 4B shows that the expression
of luciferase was dependent on the dose of soR-425 or soR-h-
425. In contrast, MHV-EFLM preincubated with soR, soR-h,
FIG. 3. Virus neutralization by the soR adapter proteins. MHV-
EFLM (MOI, 0.1) was preincubated for 1 h at 4°C with various con-
centrations of the different soR adapter proteins and inoculated onto
105 murine LR7 cells, which were then incubated for 1 h. The cells
were washed, incubation was continued, and after 7 h luciferase ex-
pression was measured. Shown is the percent neutralization, calculated
as the decrease in luciferase expression relative to infections in the
absence of adapter protein. The data represent the average of a rep-
resentative experiment performed in triplicate. Error bars indicate
standard deviations.
FIG. 4. Targeting of MHV-EFLM to human A431 cells. (A) To determine whether MHV-EFLM was able to infect human A431 cells, 104
TCID50 of MHV-EFLM were preincubated in the presence or absence of 0.5 nM soR-425. After inoculation onto 10
5 A431 cells for 1 h at 4°C,
the cells were washed and incubated further. At several time points after inoculation, intracellular luciferase expression was measured. Shown are
the data from a representative experiment. (B) MHV-EFLM (104 TCID50) was preincubated with the different soR adapter proteins at various
concentrations and inoculated onto A431 cells, which were incubated for 1 h. At 20 h after inoculation, luciferase expression was determined. All
data shown represent the average and standard deviation of an experiment performed in triplicate. RLU, relative light units; p.i., postinoculation.
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or mock supernatant did not induce detectable luciferase ex-
pression (not shown). Interestingly, whereas the presence of
the hinge region appeared to enhance the efficiency of virus
neutralization by the adapter protein (Fig. 3), it resulted in a
significant, approximately 10-fold, decrease in targeting effi-
ciency.
Soluble receptor-mediated MHV neutralization, but not tar-
geting, is affected by soR dimer formation. To further investi-
gate the effect of the hinge region in the soR proteins on MHV
neutralization and targeting, we disrupted the soR-h and soR-
h-425 dimers by treatment with the minimal concentration of
dithiothreitol (DTT) required for complete reduction of the
hinge disulfide bonds. Thus, all soR proteins were treated with
1.56 M DTT for 20 min at 4°C. Dimer dissociation was
confirmed by Western blot analysis performed under nonre-
ducing conditions (Fig. 5A). Incubation of soR-h and soR-h-
425 in the presence of DTT resulted in full reduction to mono-
mers, whereas in the absence of DTT, protein bands
corresponding to the size of dimers were detected. No effects
of the DTT treatment on soR and soR-425 migration were
observed.
Next, we analyzed whether the reduced soR-h and soR-h-
425 proteins displayed neutralization and targeting efficiencies
similar to those of their counterparts lacking the hinge region.
MHV-EFLM was inoculated onto murine LR7 cells in the
presence of the different soR proteins, each pretreated in the
presence or absence of DTT. After 7 h of incubation, the cells
were lysed and luciferase expression was measured. As shown
in Fig. 5B, after reduction the soR-h and soR-h-425 proteins
lost their enhanced neutralization capacities relative to the soR
and soR-425 proteins, which both lack the hinge dimerization
region. These results indicate that dimerization of the soR
proteins has a beneficial effect on MHV neutralization. We
also determined the effect of reduction of the soR-h-425
dimers on MHV targeting. MHV-EFLM was inoculated onto
A431 cells in the presence of 5 nM soR-425 or soR-h-425
protein, both pretreated in the presence or absence of DTT.
After 1 h, the cells were washed and incubation was continued
for 20 h, after which the cells were lysed and luciferase expres-
sion measured. Interestingly, whereas dimer reduction had a
profound effect on the neutralization capacity of soR-h-425, no
significant DTT-mediated effects on targeting efficiency were
observed (Fig. 5C).
Soluble receptor-mediated coronavirus infection is EGFR
and S protein specific. To further confirm that the infection of
MHV-EFLM established by soR-425 or soR-h-425 was indeed
mediated by the EGFR expressed on A431 cells, we studied
the effect of anti-EGFR MAb 425. A431 cells were incubated
FIG. 5. Soluble receptor-mediated MHV neutralization, but not targeting, is affected by soR dimer formation. (A) Western blot analysis of the
soR adapter proteins electrophoresed under nonreducing conditions after preincubation in the presence () or absence () of DTT. kD,
kilodaltons. (B) MHV-EFLM (MOI, 0.1) was inoculated onto murine LR7 cells, which were incubated for 1 h in the presence or absence of various
amounts of the different soR adapter proteins, which had been pretreated in the presence () or absence () of DTT. At 7 h after inoculation,
luciferase expression was determined. Shown is the percentage of neutralization, calculated as the decrease in luciferase expression relative to
infections in the absence of adapter proteins. The data represent the average of a representative experiment performed in triplicate. Error bars
indicate standard deviations. (C) MHV-EFLM (104 TCID50) was inoculated onto 10
5 A431 cells in the presence of 5 nM soR-425 or soR-h-425
protein, both pretreated in the presence () or in the absence () of 1.56 M DTT. After 1 h, the cells were washed and incubation was continued
for 20 h, after which the cells were lysed and luciferase expression measured. All data shown represent the average and standard deviation of an
experiment performed in triplicate. RLU, relative light units.
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with the antibody prior to inoculation with MHV-EFLM in the
presence of 0.5 nM soR-425 or soR-h-425 for 1 h. The cells
were then washed and incubation continued for 20 h. Figure
6A shows that infection was blocked almost completely by
MAb 425, confirming that a direct interaction with the EGFR
is required for adapter-mediated infection.
To verify that the interaction of the soR adapters with MHV
was S protein specific, MHV-EFLM or fMHV was preincu-
bated with the soR-425 or soR-h-425 protein and inoculated
onto A431 cells. The chimeric virus fMHV carries S proteins
the ectodomain of which is derived from FIPV. It infects cells
through the feline aminopeptidase N molecule rather than
murine CEACAM1a (21). Immunostaining for coronavirus
proteins was performed at 20 h after inoculation to determine
whether the A431 cells had been infected. Only the cells inoc-
ulated with MHV-EFLM stained positive, whereas cells inoc-
ulated with fMHV remained negative (Fig. 6B). These results
demonstrated that the MHV spike ectodomain is essential for
CEACAM1a N domain-mediated infection. In addition, the
immunostaining revealed the presence of large spots of fused
cells, typical for MHV infections of murine cells. The results
collectively indicate that the targeted infections of MHV in the
presence of soR-425 or soR-h-425 are dependent on interac-
tions of the adapter proteins both with the MHV spike and
with the human EGFR.
Targeted coronavirus infections require S protein-mediated
membrane fusion. Addition of a heptad repeat-mimicking pep-
tide, mHR2, during inoculation of murine LR7 cells abrogates
MHV infection by inhibition of the coalescence of the heptad
repeat regions, HR1 and HR2, required for fusion (2). In order
to investigate whether the targeted MHV infections also de-
pend on those conformational rearrangements in the viral
spike protein, we tested their sensitivity to the mHR2 peptide.
To this end, MHV-EFLM was targeted toward EGFR ex-
pressed on A431 cells with 5 nM adapter proteins soR-425 and
soR-h-425, in the presence or absence of 20 M mHR2. As
shown in Fig. 7, addition of the peptide efficiently blocked both
soR-425- and soR-h-425-mediated infections. Thus, EGFR-
FIG. 6. EGFR- and spike-specific coronavirus targeting. (A) MHV-EFLM was preincubated with soR-425 or soR-h-425 and inoculated onto
A431 cells preincubated for 1 h at 4°C in the presence or absence of anti-EGFR MAb 425. The data represent average luciferase expression relative
to that of cells inoculated in the absence of blocking antibody. Error bars show the standard deviations of experiments performed in triplicate.
(B) The specificity of the interaction of the soR adapters with the MHV spike was determined by preincubating 104 TCID50 of MHV or fMHV
in the presence or absence of the soR adapters at 0.5 nM. After 1 h, the inoculum was replaced with normal culture medium and incubation was
continued for 20 h. Polyclonal MHV antibodies were used to detect the presence of coronavirus proteins in the A431 cells at 20 h after inoculation.
Representative images are shown.
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mediated MHV infections appear to depend on conforma-
tional changes in the S protein, similar to the ones occurring
during normal infection.
Soluble receptor-mediated syncytium formation and pro-
duction of progeny virus. Interestingly, A431 cells infected by
EGFR-targeted MHV showed cell-cell fusion typical for coro-
naviruses (Fig. 6B). To investigate whether syncytium forma-
tion between infected and neighboring cells resulted from un-
defined interactions or from specific bridging by the adapter
protein, A431 cells were inoculated with MHV-EFLM in 5 nM
soR-425-containing medium for 2 h. The cells were washed
and subsequently cultured for another 22 h in the presence or
absence of 5 nM soR-425 or soR. Thus, soR-425 was either
present continuously to mediate both infection and syncytium
formation or only briefly to mediate the targeted infection.
Removal of soR-425 after 2 h did not have a significant effect
on the number of syncytia observed for each inoculated cell
culture (data not shown); however, we did observe a reduction
of the extent of syncytium formation by approximately three-
fold (Fig. 8A). The addition of soR proteins, which lack the
scFv 425 domain, did not result in increased cell-cell fusion,
indicating an EGFR-related effect. Hence, soR-425 may pro-
mote fusion not only between the MHV envelope and target
cells during virus entry but also between MHV-infected and
neighboring cells in the course of the infection process.
Finally, we determined whether the soR-425-mediated in-
fection was productive and yielded infectious virus. A431 cells
were inoculated with MHV-EFLM (MOI, 5) that had been
preincubated in the presence or absence of 5 nM soR-425 or
soR-h-425 and were then incubated for 1 h. They were then
washed and incubated further, and samples were taken from
the culture medium at different time points after inoculation
for titration on murine LR7 cells. As depicted in Fig. 8B, virus
preincubated in the presence of soR-425 or soR-h-425 pro-
duced progeny virus reaching titers of up to 105 to 106 TCID50/
ml. In contrast, inoculation with MHV-EFLM in the absence
of adapter protein did not lead to detectable virus production.
Thus, adapter-mediated redirection of MHV to human cells
results in the formation and secretion of progeny virus.
DISCUSSION
Recently, the use of viruses as potential tools to complement
the conventional treatment options for cancer therapy has
gained considerable interest (28, 30). In this study, we demon-
strate that the mouse coronavirus MHV may be an attractive
candidate for this purpose. MHV has a narrow species tropism
and a strong capacity to kill cells. These features might be used
to advantage by controlled targeting of the virus to human
tumor cells. Using the specificity of the mCEACAM1a MHV
FIG. 7. Effect of mHR2 on the bispecific adapter-mediated entry
process. A431 cells were inoculated with a preincubated mixture of
MHV-EFLM (104 TCID50) and 5 nM soR-425 or soR-h-425 in the
presence or absence of 20 M mHR2. After 1 h, the cells were washed
and incubation continued for 20 h. Finally, the cells were lysed and
luciferase activity was measured. Error bars show the standard devia-
tions of experiments performed in triplicate. RLU, relative light units.
FIG. 8. Soluble receptor-mediated syncytium formation and production of progeny virus after targeted infection. (A) A431 cells were
inoculated with MHV-EFLM in soR-425-containing medium for 2 h and subsequently cultured for another 22 h in the presence or absence of
soR-425 or soR. The cells were fixed and stained for the presence of coronavirus proteins with polyclonal MHV antibodies. The number of nuclei
of eight randomly selected syncytia per inoculated, stained cell culture was determined under a light microscope, and this was carried out in parallel
in triplicate. The data represent the average number of nuclei per syncytium, based in each case on the counting of 24 syncytia. Error bars show
the standard deviation of such an experiment. (B) MHV-EFLM was preincubated in the presence or absence of soR-425 or soR-h-425 and
inoculated onto A431 cells. After 1 h, the cells were washed and incubation was continued. At several time points thereafter, samples were taken
from the cell culture medium and subsequently titrated on murine LR7 cells to determine the amount of virus produced. The results shown are
from a representative experiment. p.i., postinoculation.
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receptor, we constructed bispecific adapter molecules com-
posed of the S protein-binding fragment of this receptor cou-
pled to an antibody fragment directed to the human EGFR,
which is known to be overexpressed on cells of many human
cancers. The adapter proteins were found to effectively medi-
ate infection of EGFR-expressing human A431 cancer cells.
Cell entry appeared to be effected through the normal spike
protein-driven membrane fusion mechanism, and the infection
resulted in efficient formation of syncytia, which we observed
earlier to ultimately lead to efficient eradication of the culture
(39).
We have shown recently that targeted entry of the feline
coronavirus FIPV and chimeric fMHV could also be accom-
plished by making use of an adapter composed of two single-
chain antibodies, one directed against the feline viral spike and
the other to the EGFR (39). Like the soR-425-mediated MHV
infections, the bispecific antibody-mediated fMHV infections
were blocked by an HR-mimicking peptide derived in this case
from the feline S protein (39). These observations suggest that
binding of the adapters to particular regions of the S protein—
i.e., the receptor-binding domain or a certain epitope—results
in conformational changes that, upon binding of the virus-
adapter complex to a cellular target receptor, facilitate inser-
tion of the fusion peptide into the cell membrane. Binding of
these adapters apparently does not inactivate the virus, as is
also indicated by studies in which MHV, purified by sedimen-
tation through a sucrose cushion after preincubation of the
virus with the soR-425 adapter protein, maintained its infec-
tivity for EGFR-positive cells (our unpublished data). These
results suggest that the adapter proteins, once bound to the
virus, may freeze the S protein in a stable prefusion confor-
mation ready to proceed to its structural rearrangements upon
contacting the target cell. What the actual trigger is that acti-
vates the fusion process is unknown, but it is quite likely that
the insertion of the fusion peptide into the cellular membrane
is a critical event.
An interesting paradox that we noticed in our studies was
the opposite efficiency of hinge-containing and hingeless
adapter molecules in neutralization and targeting. Thus, the
virus-neutralizing capacities of the adapters soR-h and soR-h-
425 were significantly higher than those of the soR and soR-
425 molecules, respectively, while the reverse was true of the
relative targeting efficiencies of soR-h-425 and soR-425 (Fig. 3
to 5). The reasons for these differences appear to be unrelated.
This can be concluded from the differential effects of reducing
agent treatment of the adapters on the two activities. Whereas
this treatment did not affect the targeting efficiencies of the
adapters, it reduced the virus-neutralizing capacities of the
hinge-containing adapters to about the level of their hingeless
counterparts, the activity of which was not significantly
changed by the treatment. Dimeric forms of the adapters ap-
parently neutralize the infectivity of the virus more efficiently
than monomers, possibly by their stronger interaction with the
spikes or their ability to cross-link spikes on the viral particle.
Remarkable as it may seem, these effects apparently have no
bearing on the efficiency of the targeting of such viral particles
or on the subsequent steps leading to membrane fusion.
Previous studies have shown that the N domain of the
mCEACAM1a receptor is sufficient by itself to induce confor-
mational changes in the MHV spike protein (22, 24, 34, 40).
Remarkably, however, this same N domain, when linked di-
rectly to the transmembrane domain, thus lacking the inter-
mediate CEACAM1a A2 domain (Fig. 1), failed to function as
a receptor for MHV (9). A possible explanation for this ob-
servation might be that the functional structure of the N do-
main is affected by linking it to the transmembrane region. This
appeared, however, not to be the case when the N domain was
replacing the corresponding domain in the mouse poliovirus
receptor homolog (25), which also belongs to the family of
Ig-like viral receptors (23). The resulting chimeric receptor
molecule functioned as a receptor for MHV (6). It is conceiv-
able that the CEACAM1a N domain needs a certain distance
from the cellular membrane to allow interaction with the S
protein to lead to effective membrane fusion. Interestingly, the
efficiency of the targeted infections described here was signif-
icantly higher with the soR-425 adapter than with the soR-h-
425 adapter, and this difference was not accounted for by the
dimeric state of a fraction of the latter, as the targeting effi-
ciency of the hinge-containing adapter was unaffected by dis-
sociation through DTT treatment. These observations indeed
suggest that also the dimensions of our adapters may affect the
efficiency of their targeting. Whether this is really the case, and
how, remains to be investigated.
The ability to target viruses by design to preselected cells is
a tremendous challenge with far-reaching implications for the
development of virus-based therapies. We previously estab-
lished the principle of retargeting of coronaviruses by exchang-
ing spike ectodomains (16, 21). Subsequent attempts to modify
the tropism of these viruses further by incorporating tumor-
binding ligands into different parts of the spike protein were
unsuccessful, as no viable viruses could be rescued (M. H.
Verheije, T. Wu¨rdinger, and P. J. M. Rottier, unpublished
data). As an alternative and potentially also versatile targeting
approach, we therefore aimed at the development of bispecific
adapters. The use of soluble receptor-based adapters to ex-
pand virus tropism has been described before for retroviruses
(32) and adenoviruses (20). Recently, also the herpes simplex
virus was redirected to a new receptor via the variable domain
of its cellular receptor, nectin 1, fused to a single-chain anti-
body (27). However, in contrast to these viruses, the corona-
virus MHV is normally incapable of infecting human cells, due
to its restricted tropism. Hence, its native tropism does not
need to be eliminated to obtain a truly targeted virus, which
avoids possible reduction of its cytotoxicity to the specific tar-
get cells. In order to fully exploit the oncolytic properties of
MHV, multiround genetic targeting will be essential. As we
described earlier, incorporation of the gene encoding the
bispecific single-chain antibody s11-425 into the adenovirus
genome leads to persistent self-targeting of the virus to a spe-
cific receptor (35). Also others showed virus retargeting by
genomically expressed bispecific adapters, though this resulted
in a reduction of the oncolytic potency of the adenovirus in the
case of the sCAR-EGF adapter (19). The same approach
seems also feasible for the development of tumor-targeted
coronaviruses. As we and others showed recently, MHV can
tolerate and express foreign genes from various insertion sites
of its genome (4, 5, 11, 12). Therefore, our next step in the
development of oncolytic coronaviruses will be to introduce
the gene encoding a bispecific adapter molecule into the virus
genome.
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